Industry Funding of Cancer Patient Advocacy Organizations
Cancer patient advocacy organizations (PAOs) often demand faster drug approval and easier access to cancer medications with uncertain benefits and harms.1 Previous research has found that a sizable percentage of PAOs across all disease types receive funding from the biopharmaceutical industry2,3; as such, the independence of such groups has been questioned.4